$CELU
Celularity Inc Stock $celu

$celu Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022024523 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022 Q2
Revenue	$4.129M	$4.135M	$3.776M
YoY Change	-14.97%	-61.07%	-35.53%
Cost Of Revenue	$5.247M	$7.213M	$3.179M
YoY Change	12.6%	212.12%	18.53%
Gross Profit	-$1.118M	-$3.078M	$597.0K
YoY Change	-670.41%	-137.04%	-81.2%
Gross Profit Margin	-27.08%	-74.44%	15.81%
Selling, General & Admin	$19.08M	$14.91M	$15.57M
YoY Change	44.46%	-31.13%	-57.32%
% of Gross Profit			2608.71%
Research & Development	$10.99M	$20.35M	$25.35M
YoY Change	-55.48%	-14.37%	-36.47%
% of Gross Profit			4246.06%
Depreciation & Amortization	$2.439M	$2.394M	$2.319M
YoY Change	-6.41%	33.59%	113.34%
% of Gross Profit			388.44%
Operating Expenses	-$22.21M	$35.26M	-$3.578M
YoY Change	-246.65%	-22.35%	-103.31%
Operating Profit	$21.10M	-$5.646M	$4.175M
YoY Change	-241.09%	-151.81%	-103.98%
Interest Expense	$210.0K	$108.0K	$41.00K
YoY Change	-127.96%	-113.71%	-103.15%
% of Operating Profit	1.0%		0.98%
Other Income/Expense, Net	$6.752M	$10.43M	$43.63M
YoY Change	-42.2%	-73.29%	-209.86%
Pretax Income	$24.45M	$4.782M	$47.84M
YoY Change	-708.13%	-90.42%	-132.77%
Income Tax	$13.00K	-$17.00K	$17.00K
% Of Pretax Income	0.05%	-0.36%	0.04%
Net Earnings	$24.43M	$4.799M	$47.83M
YoY Change	-704.8%	-90.39%	-174.18%
Net Earnings / Revenue	591.77%	116.06%	1266.58%
Basic Earnings Per Share		$0.03	$0.34
Diluted Earnings Per Share	$0.13	$0.03	$316.1K
COMMON SHARES
Basic Shares Outstanding	145.0M	142.7M	140.2M
Diluted Shares Outstanding		150.5M	151.3M

Balance Sheet

Concept	2022 Q4	2022 Q3	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.97M	$42.65M	$38.00M
YoY Change	-62.5%	-41.35%	18093233.33%
Cash & Equivalents	$13.97M	$42.65M	$38.00M
Short-Term Investments
Other Short-Term Assets	$7.262M	$6.837M	$6.161M
YoY Change	363000.0%	683600.0%	11907.41%
Inventory	$5.308M	$5.239M	$24.66M
Prepaid Expenses
Receivables	$6.966M	$8.372M	$6.633M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.50M	$63.10M	$75.45M
YoY Change	-43.31%	-30.88%	130418.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$75.66M	$77.03M	$90.57M
YoY Change	-16.52%	-15.36%
Goodwill	$119.7M	$123.3M
YoY Change	-2.93%	0.0%
Intangibles	$121.0M	$121.5M
YoY Change	-1.78%	-1.77%
Long-Term Investments
YoY Change
Other Assets	$376.0K	$401.0K	$17.91M
YoY Change	5.92%	13.28%
Total Long-Term Assets	$367.6M	$374.0M	$353.9M
YoY Change	3.53%	4.77%	175.7%
TOTAL ASSETS
Total Short-Term Assets	$33.50M	$63.10M	$75.45M
Total Long-Term Assets	$367.6M	$374.0M	$353.9M
Total Assets	$401.1M	$437.1M	$429.3M
YoY Change	-3.15%	-2.49%	234.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.810M	$9.216M	$10.23M
YoY Change	-37.64%	31.08%	65.4%
Accrued Expenses	$16.40M	$18.51M	$20.48M
YoY Change	40.66%	8.22%
Deferred Revenue	$2.273M	$2.241M
YoY Change	3.51%	10.23%
Short-Term Debt	$37.60M	$39.26M	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$62.09M	$69.22M	$32.94M
YoY Change	136.75%	136.95%	351.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$321.0K	$740.0K	$246.2M
YoY Change	-4.18%	118.93%	513.1%
Total Long-Term Liabilities	$321.0K	$740.0K	$246.2M
YoY Change	-4.18%	118.93%	513.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.09M	$69.22M	$32.94M
Total Long-Term Liabilities	$321.0K	$740.0K	$246.2M
Total Liabilities	$202.2M	$272.9M	$279.2M
YoY Change	-35.76%	-22.49%	488.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$645.5M	-$669.9M
YoY Change	-2.74%	1.56%
Common Stock	$15.00K	$14.00K
YoY Change	25.0%	40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$198.9M	$164.2M	$150.2M
YoY Change
Total Liabilities & Shareholders Equity	$401.1M	$437.1M	$429.3M
YoY Change	-3.15%	-2.49%	234.33%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022 Q2
OPERATING ACTIVITIES
Net Income	$24.43M	$4.799M	$47.83M
YoY Change	-704.8%	-90.39%	-174.18%
Depreciation, Depletion And Amortization	$2.439M	$2.394M	$2.319M
YoY Change	-6.41%	33.59%	113.34%
Cash From Operating Activities	-$29.59M	-$37.72M	-$36.32M
YoY Change	-7.68%	-51.15%	9386.22%
INVESTING ACTIVITIES
Capital Expenditures	$779.0K	-$1.563M	-$1.440M
YoY Change	-133.83%	-59.92%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$779.0K	-$1.563M	-$1.440M
YoY Change	-66.17%	-47.99%	126.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$242.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.685M	43.94M	27.72M
YoY Change	-266.17%	-55.38%	2701.97%
NET CHANGE
Cash From Operating Activities	-29.59M	-37.72M	-36.32M
Cash From Investing Activities	-779.0K	-1.563M	-1.440M
Cash From Financing Activities	1.685M	43.94M	27.72M
Net Change In Cash	-28.68M	4.656M	-10.04M
YoY Change	-18.9%	-74.47%	35186.47%
FREE CASH FLOW
Cash From Operating Activities	-$29.59M	-$37.72M	-$36.32M
Capital Expenditures	$779.0K	-$1.563M	-$1.440M
Free Cash Flow	-$30.36M	-$36.16M	-$34.88M
YoY Change	2.09%	-50.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Central Index Key EntityCentralIndexKey	0001752828
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38914
	dei	Entity Registrant Name EntityRegistrantName	Celularity Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1702591
	dei	Entity Address Address Line1 EntityAddressAddressLine1	170 Park Ave
	dei	Entity Address City Or Town EntityAddressCityOrTown	Florham Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07932
	dei	City Area Code CityAreaCode	(908)
	dei	Local Phone Number LocalPhoneNumber	768-2170
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	145013313
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42649000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37240000
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1264000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	283000
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	4452000
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2745000
CY2022Q3	celu	Promissory Notes Receivable PromissoryNotesReceivable	3920000
CY2021Q4	celu	Promissory Notes Receivable PromissoryNotesReceivable	2488000
CY2022Q3	us-gaap	Inventory Net InventoryNet	5239000
CY2021Q4	us-gaap	Inventory Net InventoryNet	9549000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6837000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7078000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	63097000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	59100000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	77032000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90625000
CY2022Q3	us-gaap	Goodwill Goodwill	123304000
CY2021Q4	us-gaap	Goodwill Goodwill	123304000
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	121547000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	123187000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13042000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14832000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14836000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	23861000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2721000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	401000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	355000
CY2022Q3	us-gaap	Assets Assets	437116000
CY2021Q4	us-gaap	Assets Assets	414128000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9216000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9317000
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18507000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11661000
CY2021Q4	celu	Financing Obligations Current FinancingObligationsCurrent	3051000
CY2022Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	39255000
CY2022Q3	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	40000000
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	39255000
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2241000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2196000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	69219000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26225000
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2120000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1871000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	158781000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	232222000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27917000
CY2021Q4	celu	Financing Obligations Noncurrent FinancingObligationsNoncurrent	28085000
CY2022Q3	celu	Warrant Liability WarrantLiability	14094000
CY2021Q4	celu	Warrant Liability WarrantLiability	25962000
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10000
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	740000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	335000
CY2022Q3	us-gaap	Liabilities Liabilities	272881000
CY2021Q4	us-gaap	Liabilities Liabilities	314710000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144524190
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144524190
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	730000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124307884
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124307884
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	14000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	833915000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	763087000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	236000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-669930000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-663681000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	164235000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99418000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	437116000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414128000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4135000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10622000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13846000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16479000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20351000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23765000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67373000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63666000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14907000
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21644000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46941000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58133000
CY2022Q3	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-33243000
CY2021Q3	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-48549000
	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-73441000
	celu	Change In Fair Value Of Contingent Consideration Liability ChangeInFairValueOfContingentConsiderationLiability	-17845000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	553000
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	553000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1640000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1640000
CY2022Q3	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	9781000
CY2021Q3	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	-276000
	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	56931000
	celu	Operating Income Costs And Expenses OperatingIncomeCostsAndExpenses	110587000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5646000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	10898000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43085000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-94108000
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	108000
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	55000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	155000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	324000
CY2021Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	843000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2412000
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9333000
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-39937000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-31613000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2258000
CY2022Q3	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	291000
	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	291000
CY2022Q3	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	1278000
CY2021Q3	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-109000
	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	1366000
	celu	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-2140000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10428000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39040000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32843000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1970000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4782000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	49938000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10242000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96078000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	4799000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	49938000
	us-gaap	Net Income Loss NetIncomeLoss	-10242000
	us-gaap	Net Income Loss NetIncomeLoss	-96078000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	236000
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	236000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	236000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	236000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5035000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49938000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10006000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96078000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48071685
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	99418000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.00
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142676953
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106369910
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	137787645
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48071685
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.00
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150546268
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123582822
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	137787645
CY2022Q1	celu	Stock Issued During Period Value Reclassification Of Previously Exercised Stock Options StockIssuedDuringPeriodValueReclassificationOfPreviouslyExercisedStockOptions	441000
CY2022Q1	celu	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	46485000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-11000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2422000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-62867000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	89905000
CY2022Q2	celu	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	4000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	313000
CY2022Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-75000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4529000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	47826000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	150150000
CY2022Q3	celu	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	399000
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4131000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4519000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent	236000
CY2022Q3	us-gaap	Profit Loss ProfitLoss	4799000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	164235000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-531400000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1009000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-81539000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-611930000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	28188000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-64477000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-648205000
CY2021Q3	celu	Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Additional Paid In Capital RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital	485596000
CY2021Q3	celu	Reclassified From Warrant Liability To Additional Paid In Capital ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital	96398000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	209000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8880000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	49938000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	96216000
	us-gaap	Profit Loss ProfitLoss	-10242000
	celu	Payments Of At The Market Offering Costs And Commissions PaymentsOfAtTheMarketOfferingCostsAndCommissions	205000
	us-gaap	Profit Loss ProfitLoss	-96078000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6997000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6211000
	celu	Non Cash Lease Expense NonCashLeaseExpense	-41000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1356000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	981000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	113000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-31613000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2258000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	11470000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	38077000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-73441000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-17845000
	celu	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	415000
	celu	Change In Fair Value Of Debt ChangeInFairValueOfDebt	291000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1432000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-3206000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2688000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	754000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16830000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3778000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-510000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1522000
	celu	Sale Of Net Operating Losses And Research And Development Tax Credits SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits	1356000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	297000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1364000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	6546000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3846000
	celu	Increase Decrease In Right Of Use Assets And Lease Liabilities IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities	195000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	294000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8633000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108291000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78051000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4457000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3900000
	celu	Proceeds From Promissory Note ProceedsFromPromissoryNote	300000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4457000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3600000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000000
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	647000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	223000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46490000
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	30000000
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	83400000
	celu	Proceeds From The Sale Of Common Stock In Atm Offering ProceedsFromTheSaleOfCommonStockInAtmOffering	4570000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2549000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9433000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118153000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	99576000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5405000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17925000
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	39200000
	celu	Proceeds From Investment ProceedsFromInvestment	20000000
	celu	Reclassification Of Option Liabilities To Equity ReclassificationOfOptionLiabilitiesToEquity	441000
	celu	Change In Pipespac Related Costs Captured In Accounts Payable And Accrued Expenses ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses	1103000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52076000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69513000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57481000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87438000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1014000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1601000
	celu	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	550113000
	celu	Cancellation Of Treasury Stock CancellationOfTreasuryStock	256000
	celu	Issuance Of Common Stock As Payment For Related Costs IssuanceOfCommonStockAsPaymentForRelatedCosts	10795000
	celu	Reclassification Of Warrant Liabilities To Equity ReclassificationOfWarrantLiabilitiesToEquity	96398000
	celu	Atm Related Costs Included In Accounts Payable And Accrued Expenses AtmRelatedCostsIncludedInAccountsPayableAndAccruedExpenses	-234000
	celu	Pipe Related Costs Included In Accrued Expenses PIPERelatedCostsIncludedInAccruedExpenses	-55000
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-08-24
CY2022Q3	celu	Number Of Clinical Trials NumberOfClinicalTrials	3
	celu	Area Of Building AreaOfBuilding	147215
	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	true
	us-gaap	Net Income Loss NetIncomeLoss	-10242000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100118000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-669930000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, and contingent stock consideration, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2022Q3	celu	Income Loss IncomeLoss	-4799000
CY2021Q3	celu	Income Loss IncomeLoss	49938000
	celu	Income Loss IncomeLoss	-10242000
	celu	Income Loss IncomeLoss	-96078000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142676953
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106369910
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	137787645
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48071685
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7857031
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	14107842
CY2022Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	12284
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3105070
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150546268
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123582822
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	137787645
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48071685
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.00
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55064893
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11467610
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65854376
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	71184264
	celu	Number Of Business Segments NumberOfBusinessSegments	3
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Customers</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of December 31, 2021, one of the Company’s customers comprised approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">47</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s total outstanding accounts receivable. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">September 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, one of the Company’s customers (Customer A) comprised approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the total outstanding gross accounts receivable and another customer (Customer B) comprised </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the total outstanding gross accounts receivable. The same two customers also provided approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s revenues earned during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">nine months ended September 30, 2022. No single customer provided 10% or more of the revenue earned during the nine months ended September 30, 2021.</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In November 2017, the FDA provided guidance that established an updated framework for regulation of Human Cell & Tissue Products (“HCT/P”). The Company’s Interfyl products meet the criteria for minimal manipulation and homologous use as outlined within the applicable guidance and has an official designation from the FDA as an HCT/P product. As a result, the Company did not stop selling its Interfyl products when the FDA ended its enforcement discretion on May 31, 2021. However, the Center for Medicare and Medicaid Services (“CMS”) began rejecting claims for Interfyl submitted by Customer A. The Company believes that CMS is not distinguishing the Interfyl products from its competitors’ products. While the Company and Customer A continue to work with CMS to resolve the rejected claims, a reserve of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> was recorded on Customer A’s accounts receivable balance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">September 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p>
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:a)each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (the “Class A Common Stock” or “Common Stock”) equal to the Exchange Ratio (as defined below) (the “Per Share Merger Consideration”);b)each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, “Legacy Celularity Capital Stock”) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;c)each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;d)each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Class A Common Stock (and not Celularity Capital Stock) (each, a “Converted Warrant”) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the “Celularity Warrant Shares”) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); ande)each option to purchase Legacy Celularity Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a “Legacy Celularity Option”) was assumed by GX and converted into an option to purchase shares of Class A Common Stock (each, a “Converted Option”).
CY2021Q3	celu	Business Acquisition Transaction Costs Proceeds Net BusinessAcquisitionTransactionCostsProceedsNet	108786000
CY2021Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	21658000
	celu	Subscription Agreements Description SubscriptionAgreementsDescription	On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc. (“Sorrento”), Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the “Subscribers”) purchased from Celularity an aggregate of 8,340,000 shares of Class A Common Stock (the “July 2021 PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the “Subscription Agreements”). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the July 2021 PIPE Shares.
CY2022Q3	celu	Convertible Note Receivable ConvertibleNoteReceivable	3920000
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	44154000
CY2022Q3	celu	Contingent Stock Consideration ContingentStockConsideration	415000
CY2022Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	39255000
CY2022Q3	celu	Warrant Liability Private Investment In Public Equity Warrants WarrantLiabilityPrivateInvestmentInPublicEquityWarrants	3813000
CY2022Q3	celu	Warrant Liability Sponsor Warrants WarrantLiabilitySponsorWarrants	4675000
CY2022Q3	celu	Warrant Liability Public Warrants WarrantLiabilityPublicWarrants	5606000
CY2022Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	212545000
CY2021Q4	celu	Convertible Note Receivable ConvertibleNoteReceivable	2488000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	39188000
CY2021Q4	celu	Warrant Liability Sponsor Warrants WarrantLiabilitySponsorWarrants	13600000
CY2021Q4	celu	Warrant Liability Public Warrants WarrantLiabilityPublicWarrants	12362000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	258184000
	celu	Fair Value Assets Level One To Level Two Transfers Amount During Period FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod	0
	celu	Fair Value Assets Level Two To Level One Transfers Amount During Period FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021Q4	celu	Contingent Consideration Obligation ContingentConsiderationObligation	232222000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-73026000
CY2022Q3	celu	Contingent Consideration Obligation ContingentConsiderationObligation	159196000
CY2022Q3	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	14094000
CY2021Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	25962000
CY2020Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	76640000
CY2021	celu	Gain Loss Recognized In Earnings From Change In Fair Values GainLossRecognizedInEarningsFromChangeInFairValues	13482000
CY2021	celu	Reclassification Of Legacy Celularity Warrants To Equity ReclassificationOfLegacyCelularityWarrantsToEquity	-96398000
CY2021Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	25962000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1640000
CY2022Q3	celu	Valuation Input For Short Term Debt Credit Spread ValuationInputForShortTermDebtCreditSpread	0.1482
CY2022Q3	celu	Valuation Input For Short Term Debt Dividend Yield ValuationInputForShortTermDebtDividendYield	0
CY2021Q4	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	25962000
	celu	Private Investment In Public Equity Warrant Issuance PrivateInvestmentInPublicEquityWarrantIssuance	19745000
	celu	Gain Loss Recognized In Earnings From Change In Fair Values GainLossRecognizedInEarningsFromChangeInFairValues	31613000
CY2022Q3	celu	Fair Value Net Assets Liability FairValueNetAssetsLiability	14094000
CY2022Q3	celu	Face Value Of Notes Receivable FaceValueOfNotesReceivable	4000000
CY2021Q4	celu	Face Value Of Notes Receivable FaceValueOfNotesReceivable	4000000
CY2022Q3	celu	Valuation Model That Relate To Sanuwave Common Stock ValuationModelThatRelateToSanuwaveCommonStock	0.06
CY2021Q4	celu	Valuation Model That Relate To Sanuwave Common Stock ValuationModelThatRelateToSanuwaveCommonStock	0.17
	celu	Scheduleofyorkvilleshort Termdebtvaluationmodel Tabletextblock ScheduleofyorkvilleshortTermdebtvaluationmodelTabletextblock	<p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Significant inputs for the Yorkville short-term debt valuation model are as follows:</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.278%;"/> <td style="width:1.92%;"/> <td style="width:1.0%;"/> <td style="width:16.801000000000002%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">September 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Common share price</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.31</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Credit spread</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14.82</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Dividend yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Term (years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.0</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.04</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Volatility</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">45.0</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Discount yield</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18.86</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2022Q3	celu	Valuation Input For Short Term Debt Share Price ValuationInputForShortTermDebtSharePrice	2.31
CY2021Q4	us-gaap	Goodwill Goodwill	123304000
CY2022Q3	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	29100000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1640000
	celu	Valuation Input For Short Term Debt Term ValuationInputForShortTermDebtTerm	P1Y
CY2022Q3	celu	Valuation Input For Short Term Debt Discount Yield ValuationInputForShortTermDebtDiscountYield	0.1886
CY2022Q3	celu	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	9565000
CY2021Q4	celu	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	2359000
CY2022Q3	celu	Inventory Work In Progress Current And Noncurrent InventoryWorkInProgressCurrentAndNoncurrent	9942000
CY2021Q4	celu	Inventory Work In Progress Current And Noncurrent InventoryWorkInProgressCurrentAndNoncurrent	5902000
CY2022Q3	celu	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	9797000
CY2021Q4	celu	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	4057000
CY2022Q3	celu	Inventory Gross Current And Noncurrent InventoryGrossCurrentAndNoncurrent	29304000
CY2021Q4	celu	Inventory Gross Current And Noncurrent InventoryGrossCurrentAndNoncurrent	12318000
CY2022Q3	celu	Inventory Reserve Current And Noncurrent InventoryReserveCurrentAndNoncurrent	204000
CY2021Q4	celu	Inventory Reserve Current And Noncurrent InventoryReserveCurrentAndNoncurrent	48000
CY2021Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	12270000
CY2022Q3	us-gaap	Inventory Net InventoryNet	5239000
CY2021Q4	us-gaap	Inventory Net InventoryNet	9549000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	23861000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2721000
CY2022Q3	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	29100000
CY2021Q4	celu	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	12270000
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95482000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	105404000
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18450000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14779000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	77032000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90625000
CY2021Q4	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	5971000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1841000
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1792000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5357000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4571000
CY2022Q3	us-gaap	Goodwill Goodwill	123304000
	celu	Indefinite Lived Intangible Assets Amortization Method IndefiniteLivedIntangibleAssetsAmortizationMethod	indefinite
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	121547000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	123187000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	553000
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	553000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23993000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23993000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10946000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9306000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13047000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14687000
CY2022Q3	celu	Acquired Product Rights AcquiredProductRights	108500000
CY2021Q4	celu	Acquired Product Rights AcquiredProductRights	108500000
CY2021	celu	Indefinite Lived Intangible Assets Amortization Method IndefiniteLivedIntangibleAssetsAmortizationMethod	indefinite
CY2022Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2021Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	2880000
	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	760000
CY2022Q2	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	957000
CY2021Q2	celu	Operating Leases Rent Expense OperatingLeasesRentExpense	0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90625000
CY2021Q4	celu	Current Portion Of Financing Obligation CurrentPortionOfFinancingObligation	3051000
CY2021Q4	celu	Operating Lease Financing Obligations Noncurrent OperatingLeaseFinancingObligationsNoncurrent	28085000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-663681000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	759000
	us-gaap	Operating Lease Cost OperatingLeaseCost	2278000
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	448000
	us-gaap	Variable Lease Cost VariableLeaseCost	1140000
CY2022Q3	us-gaap	Lease Cost LeaseCost	1207000
	us-gaap	Lease Cost LeaseCost	3418000
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	46000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	126000
	us-gaap	Operating Lease Payments OperatingLeasePayments	2125000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	708000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2895000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2969000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3042000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3116000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3190000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	70342000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	86262000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	58345000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	27917000
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P23Y4M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1112
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	common stock are entitled to one vote per share
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	33458460
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.026
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.771
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.60
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.13
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	587000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4519000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8880000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11470000
	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	12161000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38077000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4135000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10622000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13846000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16479000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4067000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12449000
	celu	Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue	3699000
	celu	Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue	3528000
	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	3405000
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4361000
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3816000
CY2021Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6754000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2022Q3	us-gaap	Assets Assets	437116000
CY2021Q4	us-gaap	Assets Assets	414128000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4135000
CY2022Q3	us-gaap	Gross Profit GrossProfit	-3078000
CY2022Q3	us-gaap	Direct Operating Costs DirectOperatingCosts	35454000
CY2022Q3	celu	Segment Contribution SegmentContribution	-38532000
CY2022Q3	celu	Indirect Expenses IndirectExpenses	-32886000
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5646000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10622000
CY2021Q3	us-gaap	Gross Profit GrossProfit	8311000
CY2021Q3	us-gaap	Direct Operating Costs DirectOperatingCosts	45409000
CY2021Q3	celu	Segment Contribution SegmentContribution	-37098000
CY2021Q3	celu	Indirect Expenses IndirectExpenses	-47996000
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	10898000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13846000
	us-gaap	Gross Profit GrossProfit	-572000
	us-gaap	Direct Operating Costs DirectOperatingCosts	113899000
	celu	Segment Contribution SegmentContribution	-114471000
	celu	Indirect Expenses IndirectExpenses	-71386000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-43085000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16479000
	us-gaap	Gross Profit GrossProfit	11486000
	us-gaap	Direct Operating Costs DirectOperatingCosts	121799000
	celu	Segment Contribution SegmentContribution	-110313000
	celu	Indirect Expenses IndirectExpenses	-16205000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-94108000

Files In Submission

Name	View Source	Status
0000950170-22-024523-index-headers.html	Edgar Link	pending
0000950170-22-024523-index.html	Edgar Link	pending
0000950170-22-024523.txt	Edgar Link	pending
0000950170-22-024523-xbrl.zip	Edgar Link	pending
celu-20220930.htm	Edgar Link	pending
celu-20220930.xsd	Edgar Link	pending
celu-ex10_1.htm	Edgar Link	pending
celu-ex10_10.htm	Edgar Link	pending
celu-ex10_11.htm	Edgar Link	pending
celu-ex10_12.htm	Edgar Link	pending
celu-ex10_4.htm	Edgar Link	pending
celu-ex10_5.htm	Edgar Link	pending
celu-ex10_6.htm	Edgar Link	pending
celu-ex10_7.htm	Edgar Link	pending
celu-ex10_8.htm	Edgar Link	pending
celu-ex10_9.htm	Edgar Link	pending
celu-ex31_1.htm	Edgar Link	pending
celu-ex31_2.htm	Edgar Link	pending
celu-ex32_1.htm	Edgar Link	pending
celu-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img259357917_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
celu-20220930_cal.xml	Edgar Link	unprocessable
celu-20220930_def.xml	Edgar Link	unprocessable
celu-20220930_lab.xml	Edgar Link	unprocessable
celu-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celu-20220930_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELU
Celularity Inc Stock $celu

2022 Q4 Form 10-Q Financial Statement

#000095017022024523 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELU Celularity Inc Stock $celu

2022 Q4 Form 10-Q Financial Statement

#000095017022024523 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELU
Celularity Inc Stock $celu